-PEARL-SC Trial Continues as Planned-
-VISTA-16 Interim Analysis to Occur Next Week-
Report is Available for Download at: www.lifesciadvisors.com/clients/anthera
Yesterday morning, Anthera Pharmaceuticals (NASDAQ: ANTH) issued a press release and announced the completion of the fourth PEARL-SC Data Safety Monitoring Board (DSMB) review and an interim efficacy analysis by an independent statistician. We report that both parties recommend that the Phase IIb PEARL-SC Study continues as planned.
The Phase IIb PEARL-SC Study (n=547) is examining the ability of weekly and monthly subcutaneous injections of blisibimod to provide therapeutic benefit to patients with Lupus. The primary endpoint is clinical improvement at 24 weeks in a SLE responder index.
DSMB Review Recommends that Study Continue as Planned. With regards to the fourth DSMB safety review for the PEARL-SC study, the board recommended that the study continued as planned with no modifications to study protocol. This result was expected by many investors, but it is still a good sign of the continued strong safety profile of blisibimod.